ArriVent BioPharma (AVBP) Income from Non-Controlling Interests (2025 - 2026)
ArriVent BioPharma (AVBP) reported Income from Non-Controlling Interests of -$284000.0 for Q1 2026, down 246.39% on a YoY basis from $194000.0 in Q1 2025, and down 46.39% sequentially from -$194000.0 in Q4 2025.
ArriVent BioPharma (AVBP) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$284000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 246.39% year-over-year to -$284000.0; the trailing twelve-month figure through Mar 2026 stood at -$253000.0 (changed N/A YoY), and the FY2025 full-year result was $225000.0, up 206.64% from the prior year.
- Income from Non-Controlling Interests declined to -$284000.0 in Q1 2026, from -$194000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $226000.0 in Q3 2025 to a low of -$284000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | -284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -284,000.00 |
| Dec 31, 2025 | -194,000.00 |
| Sep 30, 2025 | 226,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 194,000.00 |